.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
McKesson
Cipla
Covington
Federal Trade Commission
McKinsey
US Army
Novartis
Accenture
Mallinckrodt

Generated: June 26, 2017

DrugPatentWatch Database Preview

LOSEASONIQUE Drug Profile

« Back to Dashboard

What is the patent landscape for Loseasonique, and what generic Loseasonique alternatives are available?

Loseasonique is a drug marketed by Teva Branded Pharm and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-eight patent family members in twenty-two countries.

The generic ingredient in LOSEASONIQUE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

Summary for Tradename: LOSEASONIQUE

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list3
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LOSEASONIQUE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm
LOSEASONIQUE
ethinyl estradiol; levonorgestrel
TABLET;ORAL022262-001Oct 24, 2008ABRXNoNo7,858,605► SubscribeY ► Subscribe
Teva Branded Pharm
LOSEASONIQUE
ethinyl estradiol; levonorgestrel
TABLET;ORAL022262-001Oct 24, 2008ABRXNoNo7,855,190► Subscribe ► Subscribe
Teva Branded Pharm
LOSEASONIQUE
ethinyl estradiol; levonorgestrel
TABLET;ORAL022262-001Oct 24, 2008ABRXNoNo7,615,545► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LOSEASONIQUE

Drugname Dosage Strength RLD Submissiondate
levonorgestrel;ethinyl estradiol;ethinyl estradiolTablets0.1 mg/0.02 mg and 0.01 mgLoSeasonique11/16/2009

Non-Orange Book Patents for Tradename: LOSEASONIQUE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,772,219Methods of hormonal treatment utilizing extended cycle contraceptive regimens► Subscribe
7,320,969Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology► Subscribe
8,680,084Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology► Subscribe
8,338,396Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LOSEASONIQUE

Country Document Number Estimated Expiration
Poland213122► Subscribe
Australia2010201022► Subscribe
New Zealand555299► Subscribe
World Intellectual Property Organization (WIPO)2004098517► Subscribe
Russian Federation2351339► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LOSEASONIQUE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0160011 00192Estonia► SubscribePRODUCT NAME: LEVONORGESTREEL JA ETUENUEUELOESTRADIOOL;REG NO/DATE: EE 894715 11.11.2015
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Farmers Insurance
Deloitte
Chubb
Moodys
Federal Trade Commission
Julphar
Express Scripts
US Department of Justice
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot